|
|
Article: Ads may jolt pill sales: The FDA approved Takeda Pharmaceuticals' Rozerem almost a year ago, but the firm held off heavy marketing of the insomnia pill until after talking about it with doctors. It has side effects, but it is.
- Article from:
- Chicago Tribune (Chicago, IL)
- Article date:
- July 16, 2006
|
Copyright informationCOPYRIGHT 2006 Chicago Tribune. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Bruce Japsen
Jul. 16--Hoping to help Americans snooze while also putting to rest controversies dogging the crowded group of prescription sleeping pills, a Chicago-area drugmaker this week will launch a nearly $100 million consumer ad campaign for its insomnia pill. Takeda Pharmaceuticals North America Inc. on Monday will launch an ad campaign directed at consumers for its new sleeping pill, Rozerem, which the Food and Drug Administration approved last year as the first sleeping medication not designated as a controlled substance, therefore lacking potential for abuse. The company and studies indicate the drug lacks the risk of chemical abuse or dependency ...
Related newspaper, magazine, and journal articles:
|
|
Article: Compliance and side effects
Pharmaceutical Executive;
May 1, 2003 ;
700+ words
......for many reasons-cost, low motivation, ineffective therapy-but the most important by far is side effects. Actual side effects, perceived side effects, fear of side effects: these are the main reasons that people avoid or quit treatment. Patients...
|
|